Sam Hocking
Associate Professor Samantha "Sam" Hocking is an Endocrinologist at Royal Prince Alfred Hospital and Clinical Academic at the University of Sydney, specializing in obesity, type 2 diabetes, and incretin (GLP-1) therapies.
1
APPEARANCES
1
PODCASTS
Aug 24, 2026
speaker_0HOST
three to five years.
Sam HockingGUEST
So a number of different agents, you can see that they're working on a number of different receptors.
Sam HockingGUEST
We actually have in the case of Maritide, a GIP-1 receptor agonist with a GIP receptor antagonist that has just published phase two trials that look really promising.
Sam HockingGUEST
There's an oral non-peptide GLP-1 coming to the market, hopefully in the next two to three years called Orphoglipron.
Sam HockingGUEST
And then Kagrisema has also just published phase three data at the American Diabetes Association meeting, which is an amylin and GLP-1 receptor agonist.
11 MINS LATER
speaker_0HOST
is semaglutide